European drug regulators have approved the experimental drug Forxiga, known by the generic name dapagliflozin, a once-daily pill for adult type 2 diabetes. It is the first drug approved in a new class of medications called SGLT2 inhibitors. The same drug was rejected in January by the U.S. Food and Drug Administration (FDA) because of concerns that the medication increased the risk of bladder cancer and breast cancer. Dapagliflozin works by increasing renal glucose elimination, thereby allowing more sugar to be excreted in the urine. During clinical trials nine out of 5,478 patients who were taking the drug were diagnosed ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.